Acute myeloid leukemia and down syndrome evolution of modern therapy - State of the art review

Pediatric Blood and Cancer

Volumn 44, Issue 1, 2005, Pages 13-20

  Gamis, Alan S ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

AML; Chemotherapy; Down syndrome; Leukemia

Indexed keywords

AMSACRINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; AZACITIDINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MEPREDNISONE; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PIRARUBICIN; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DOWN SYNDROME; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; LUNG DISEASE; MORTALITY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN MANIFESTATION; TREATMENT OUTCOME;

ACUTE DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DOWN SYNDROME; HUMANS; LEUKEMIA, MYELOID; PROGNOSIS; RISK ASSESSMENT;

EID: 10044278287     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20207     Document Type: Review

References (22)

1. Krivit W, Good RA. Simultaneous occurrence of monogolism and leukemia. Arch Dis Child 1957;94:289-293.
2. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Hematol 2000;110:512-524.
3. Lange B, Kobrinsky N, Barnard D, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down Syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 1998;91: 608-615.
4. Gamis A, Woods W, Alonzo T, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: A report from the Children's Cancer Group study 2891. J Clin Oncol 2003;21:3415-3422.
5. Robison L, Nesbit M, Sather H, et al. Down syndrome and acute leukemia in children: A 10-year retrospective survey from Children's Cancer Study Group. J Pediatr 1984;105:235-242.
6. Levitt G, Stiller C, Chessells J. Prognosis of Down's syndrome with acute leukaemia. Arch Dis Child 1990;65:212-216.
7. Zipursky A, Thorner P, De Harven E, et al. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res 1994;18:163-171.
8. Ravindranath Y, Abella E, Krischer J, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on pediatric oncology group AML study 8498. Blood 1992;80:2210-2214.
9. Ravindranath Y, Steuber C, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: A pediatric oncology group study. J Clin Oncol 1991;9:572-580.
10. Lie S, Jonmundsson G, Mellander L, et al. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: Best outcome in girls, infants, and children with Down's syndrome. Br J Hematol 1996;94:82-88.
11. Creutzig U, Ritter J, Vormoor J, et al. Myelodysplasia and acute myelogenous leukemia in Down's Syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia 1996;10: 1677-1686.
12. Creutzig U, Ritter J, Zimmerman M, et al. Does cranial radiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood acute myelogenous leukemia study BF-87. J Clin Oncol 1993;11:279-286.
13. Craze J, Harrison G, Wheatley K, et al. Improved outcome of acute myeloid leukaemia in Down's syndrome. Arch Dis Child 1999;81:32-37.
14. Stevens R, Hann I, Wheatley K, et al. Marked improvements in outcome with chemotherapy along in paediatric acute myeloid leukaemia: Results of the United Kingdom medical research Council's 10th AML trial. Br J Hematol 1998;101:130-140.
15. Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia 2000;14:786-791.
16. Mundshau G, Gurbuxani S, Gamis A, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 2003;101:4298-4300.
17. Hitzler J, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryocytic leukemia of Down syndrome. Blood 2003;101:4301-4304.
18. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003;102:981-986.
19. Gurbuxani S, Vyas P, Crispino J. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 2004;103:399-406.
20. Taub J, Matherly L, Stout M, et al. Enhanced metabolism of 1-B-D-Arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 1996;87:3395-3403.
21. Taub J, Huang X, Matherly L, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999;94:1393-1400.
22. Zwaan C, Kaspers G, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002;99:245-251.